Compare · CRVO vs LLY
CRVO vs LLY
Side-by-side comparison of CervoMed Inc. (CRVO) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRVO and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.06T, about 25259.7x CRVO ($41.8M).
- Over the past year, CRVO is down 37.7% and LLY is up 39.0% - LLY leads by 76.7 points.
- CRVO has been more active in the news (16 items in the past 4 weeks vs 15 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 11 for CRVO).
- Company
- CervoMed Inc.
- Eli Lilly and Company
- Price
- $4.52+78.66%
- $1122.43-0.64%
- Market cap
- $41.8M
- $1.06T
- 1M return
- +29.51%
- +11.72%
- 1Y return
- -37.66%
- +39.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 16
- 15
- Recent ratings
- 11
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CRVO
- Wall Street Chases the Next Big Breakout
- Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
- Director Boger Joshua S bought $3,000,000 worth of shares (955,414 units at $3.14) (SEC Form 4)
- CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
- SEC Form 4 filed by Director Zavrl Frank
- SEC Form 4 filed by Director Sabbagh Marwan
- SEC Form 4 filed by Director Quigley David
- SEC Form 4 filed by Director Poulton Jeffrey V.
- SEC Form 4 filed by Director Hollingsworth Jane H
Latest LLY
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,401 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,723 units (SEC Form 4)
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode